Company intelligence / Profile preview

ARNA Genomics

Orange County, California, United Statesarna.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

ARNA Genomics has developed a liquid biopsy platform with high reported accuracy (>90%) for early breast cancer detection. Their lead product, "ARNA Breast," is undergoing clinical validation. Over 600 patients have been involved in studies to date. The company claims over nine years of experience and leverages novel genome-wide methylation analysis technologies.[3][5]

Therapeutic areas: Oncology
Modalities: Liquid biopsyMultiomics diagnosticsNucleic acid detection (DNA methylation analysis)
Industry: Molecular Diagnostics

Drug pipeline

2 assets

ARNA-1

Pre-clinical

Indications: Cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on ARNA Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARNA Genomics.

Explore the full profile